Tomáš Büchler
Charles University · 427 works · 6,483 citations · h-index 35
Top works
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
- 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
- Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
- 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
- Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
- Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients
- Cancer Incidence and Mortality in the Czech Republic
- Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer
- Langerhans cell histiocytosis with central nervous system involvement: Follow‐up by FDG‐PET during treatment with cladribine
- Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease
- Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry
- Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
- Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis
- Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab
- FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease-a useful tool for monitoring pulmonary toxicity and disease activity
- Single Nucleotide Polymorphisms within Interferon Signaling Pathway Genes Are Associated with Colorectal Cancer Susceptibility and Survival